Senate to ignore OTC regulatory arbitrage

Despite recent fears that the US and Europe are diverging on OTC derivatives regulation, the US Senate is unlikely to consider the prospect of regulatory arbitrage when legislating

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login
We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree